Page Title
Clinical Trial Finder
Blaze a trail to better treatments and a cure for cystic fibrosis.
As a clinical trial volunteer, you are paving the way for new treatments. Search for trials that may be right for you using the filter on the left, or learn how to use the finder by watching this video.
Showing 1-12 of 16 studies
As a clinical trial volunteer, you are paving the way for new treatments. Search for trials that may be right for you using the filter on the left, or learn how to use the finder by watching this video.
Showing 1-12 of 16 studies
-
Genetic TherapyEnrolling
Study of 4D-710 in Adults with Cystic Fibrosis , protocol number 4DMT 4D-710-C001 (Part 1 and 2)This study will test the safety and tolerability of 4D-710, an investigational gene therapy, in adults with CF who are not eligible for or are unable to tolerate CFTR modulator therapy.
-
Age:
18 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
50 to 100%
-
Number of Visits:
11
-
Length of Participation:
2 years
-
-
Anti-InflammatoryEnrolling
Study to evaluate BI 1291583 in adults with cystic fibrosis bronchiectasis. , protocol number Boehringer Ingelheim BI1397-0013BI 1291583 is a potential therapy intended to reduce inflammation in the lungs of people with bronchiectasis, the progressive lung disease that occurs in cystic fibrosis and other conditions. This study will test the safety, tolerability, and the effect on the body of BI 1291583.
-
Age:
18 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
No FEV1 Limit
-
Number of Visits:
7
-
Length of Participation:
22 weeks
-
-
Anti-InfectiveEnrolling
Study of CMTX-101 in adults with cystic fibrosis chronically infected with Pseudomonas aeruginosa , protocol number Clarametyx CMTX101-P1-CT002 Part 2This study will test the safety and tolerability of a single dose of CMTX-101 delivered through an IV infusion. CMTX-101 is a drug intended to help treat infections in the lung.
-
Age:
18 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
35% or greater
-
Number of Visits:
9
-
Length of Participation:
8 weeks
-
-
Anti-InfectiveEnrolling
Study of CMTX-101 in adults with cystic fibrosis chronically infected with Pseudomonas aeruginosa , protocol number Clarametyx CMTX101-P1-CT002 SADThis study will test the safety and tolerability of a single dose of CMTX-101 delivered through an IV infusion. CMTX-101 is a drug intended to help treat infections in the lung.
-
Age:
18 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
50% or greater
-
Number of Visits:
9
-
Length of Participation:
8 weeks
-
-
Anti-InfectiveEnrolling
Study to evaluate inhaled RSP-1502 in adults with cystic fibrosis and Pseudomonas aeruginosa , protocol number Respirion RESPIR-102This study will look at the safety of inhaled RSP-1502, a drug intended to treat infections in the lung. RSP-1502, which includes the antibiotic tobramycin, will be compared to tobramycin alone. The study will measure the drug's safety, how well it works, and how the body processes it. Four doses of RSP-1502 will be tested to find the best dose.
-
Age:
18 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
40 to 90%
-
Number of Visits:
5
-
Length of Participation:
28 days
-
-
Anti-InfectiveEnrolling
Study to evaluate the standardizing of treatment for pulmonary exacerbations in children and adults with CF ages 6 and older. , protocol number STOP360-IP-22This study will look at pulmonary exacerbations, which are a worsening of respiratory symptoms, in people with CF who need to be treated with intravenous (IV) antibiotics. It will compare treatment with one antibiotic (a beta-lactam) to treatment with two antibiotics (tobramycin and a beta-lactam) to learn whether there is a difference in lung function and symptom improvement between the two groups. This study is for people ages 6 and older.
-
Age:
6 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
No FEV1 Limit
-
Number of Visits:
3
-
Length of Participation:
48 days
-
-
Anti-InfectiveEnrolling
ABATE: Study to evaluate IV gallium in adults with cystic fibrosis who have nontuberculous mycobacteria (NTM) , protocol number ABATE-IP-18This study is taking place at multiple care centers across the U.S. It will look at the safety and tolerability of IV gallium, a drug intended to treat infections in the lung.
-
Age:
18 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
25% or greater
-
Number of Visits:
8
-
Length of Participation:
20 weeks
-
-
Nutritional-GIEnrolling
Study to evaluate ANG003 enzyme therapy in adults with cystic fibrosis who have pancreatic insufficiency. , protocol number Anagram ANG003-22-101This phase 1 study will evaluate the safety, tolerability, and effectiveness of a single dose of ANG003. One dose of the study drug will be given in place of a participant's usual pancreatic enzymes.
-
Age:
18 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
No FEV1 Limit
-
Number of Visits:
4
-
Length of Participation:
23 days
-
-
ObservationalEnrolling
A study of strength and muscle development to assess nutrition and lung function in people with CF ages 18 and older. , protocol number STRONG-CFThis observational study will look at physical measurements, including body mass index and body composition, and compare them to bone density scans. This study includes measurements of arm circumference, hand-grip strength, distance walked in 6 minutes, and lung function.
-
Age:
18 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
No FEV1 Limit
-
Number of Visits:
5
-
Length of Participation:
12 months
-
-
ObservationalEnrolling
Observational study of adults with cystic fibrosis for colorectal cancer screening (NICE-CF) , protocol number NICE-CFThis observational study will compare stool-based testing to colonoscopy for colorectal cancer screening in people with CF. The study includes the collection of stool samples at home and a clinical screening colonoscopy.
-
Age:
18 Years to 75 Years
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
No FEV1 Limit
-
Number of Visits:
2
-
Length of Participation:
6 months
-
-
ObservationalEnrolling
MAYFLOWERS: Study of pregnancy in women with cystic fibrosis , protocol number MAYFLOWERS-OB-20This observational study will evaluate the effects of CFTR modulators on women with CF during and after pregnancy. CFTR modulators are intended to help CFTR protein function closer to normal.
-
Age:
16 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
No FEV1 Limit
-
Number of Visits:
9
-
Length of Participation:
35 months
-
-
ObservationalEnrolling
Study to evaluate the effects of CFTR modulators in infants and young children (BEGIN Part B) , protocol number BEGIN-OB-19 Part BThis two-part observational study will look at the effects of CFTR modulators on growth in young children with CF. These drugs are intended to help CFTR protein function closer to normal.
-
Age:
Less than 6 Years
-
Mutation(s):
Mutation Requirement
-
FEV1% Predicted:
No FEV1 Limit
-
Number of Visits:
6
-
Length of Participation:
2 years
-
Studies in this tool are multi-center studies facilitated by the Cystic Fibrosis Therapeutics Development Network. For a complete list of cystic fibrosis related studies, visit www.clinicaltrials.gov.
Related Topics
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Check the Drug Development Pipeline
We’re attacking CF from every angle. Learn about the status of CF drugs in development.
Learn More